Concerning IDO2 evaluation, the majority of the tumors (160 cases, 84%) belonged to the high expression group of this molecule, both among adenocarcinomas (112; 92%) and among squamous cell carcinomas (48; 70%, Table 1). This evidence concerns the gene IDO2 and adenocarcinoma.